Successful Treatment of Chronic Antibody-Mediated Rejection With IVIG and Rituximab in Pediatric Renal Transplant Recipients | Zendy

Heiko Billing | Zendy; Susanne Rieger | Zendy; Jörg Ovens | Zendy; Caner Süsal | Zendy; Anette Melk | Zendy; Rüdiger Waldherr | Zendy; Gerhard Opelz | Zendy; Burkhard Tönshoff | Zendy

Open Access

Successful Treatment of Chronic Antibody-Mediated Rejection With IVIG and Rituximab in Pediatric Renal Transplant Recipients

Author(s) -

Heiko Billing,

Susanne Rieger,

Jörg Ovens,

Caner Süsal,

Anette Melk,

Rüdiger Waldherr,

Gerhard Opelz,

Burkhard Tönshoff

Publication year - 2008

Publication title -

transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.45

H-Index - 204

eISSN - 1534-6080

pISSN - 0041-1337

DOI - 10.1097/tp.0b013e3181880b35

Subject(s) - rituximab , medicine , renal function , regimen , urology , gastroenterology , antibody , transplantation , cd20 , immunology

Chronic antibody-mediated rejection (CAMR) of renal allografts has recently been recognized as a defined nosologic entity. The outcome of CAMR is poor; there is no established treatment protocol for this condition. We therefore initiated a pilot study on treatment of CAMR with an antihumoral regimen consisting of high-dose intravenous immunoglobulin (IVIG) and the chimeric anti-CD20 antibody rituximab.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research